OraSure Technologies, Inc. $OSUR Shares Sold by Hsbc Holdings PLC

Key Points

• Hsbc Holdings PLC has reduced its stake in OraSure Technologies, Inc. by 60.2%, selling 140,805 shares in the first quarter and now owning approximately 92,980 shares worth $310,000.
• Various institutional investors have recently increased their stakes in OraSure Technologies, with 93.50% of the stock now owned by institutional investors.
• OraSure's stock is currently trading at $3.14, down 6.5%, with a consensus rating of "Hold" and an average price target of $3.00 according to analysts.

Hsbc Holdings PLC decreased its holdings in shares of OraSure Technologies, Inc. (NASDAQ:OSUR - Free Report) by 60.2% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 92,980 shares of the medical instruments supplier's stock after selling 140,805 shares during the period. Hsbc Holdings PLC owned about 0.12% of OraSure Technologies worth $310,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds have also recently modified their holdings of the company. Private Management Group Inc. bought a new position in OraSure Technologies in the 1st quarter worth $14,886,000. Gagnon Securities LLC bought a new position in OraSure Technologies in the 1st quarter worth $3,619,000. D. E. Shaw & Co. Inc. boosted its holdings in OraSure Technologies by 180.5% in the 4th quarter. D. E. Shaw & Co. Inc. now owns 1,517,541 shares of the medical instruments supplier's stock worth $5,478,000 after buying an additional 976,475 shares during the period. Gagnon Advisors LLC bought a new position in OraSure Technologies in the 1st quarter worth $2,687,000. Finally, Systematic Financial Management LP boosted its holdings in OraSure Technologies by 33.7% in the 4th quarter. Systematic Financial Management LP now owns 1,673,609 shares of the medical instruments supplier's stock worth $6,042,000 after buying an additional 421,497 shares during the period. Institutional investors own 93.50% of the company's stock.

Wall Street Analysts Forecast Growth

OSUR has been the subject of several recent analyst reports. Wall Street Zen raised shares of OraSure Technologies from a "sell" rating to a "hold" rating in a report on Saturday, May 17th. Evercore ISI reiterated an "in-line" rating and issued a $3.00 price target on shares of OraSure Technologies in a research note on Monday, May 19th. One research analyst has rated the stock with a Hold rating, Based on data from MarketBeat, the company currently has an average rating of "Hold" and a consensus target price of $3.00.

OraSure Technologies Price Performance

Shares of NASDAQ:OSUR traded up $0.10 during trading on Tuesday, reaching $3.35. 63,279 shares of the company were exchanged, compared to its average volume of 750,051. The firm has a market capitalization of $244.65 million, a PE ratio of -4.99 and a beta of 0.44. The business's fifty day simple moving average is $3.10 and its 200-day simple moving average is $3.07. OraSure Technologies, Inc. has a 12-month low of $2.36 and a 12-month high of $4.60.

OraSure Technologies Profile

OraSure Technologies, Inc, together with its subsidiaries, provides point-of-care and home diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services in the United States, Europe, and internationally. The company's products include InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test, OraQuick Ebola rapid antigen test, OraSure oral fluid collection device used in conjunction with screening and confirmatory tests for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D.